The Department of Health and Human Services today announced a $628 million agreement with Emergent BioSolutions to advance manufacturing capabilities and capacity for a potential COVID-19 vaccine and therapeutics as part of Operation Warp Speed.

“Before a vaccine is even approved, Emergent’s manufacturing capabilities will pave the way for drug companies with candidates approaching approval to begin turning out doses,” said HHS Secretary Alex Azar. “Securing more manufacturing capacity here in America for candidates that make it to the final stages of Operation Warp Speed will help get a vaccine to American patients without a day wasted.”

Related News Articles

Headline
The Food and Drug Administration and Centers for Disease Control and Prevention July 7 at 12 p.m. ET will host a webinar on decontaminating respirators for…
Headline
The blanket data reporting exceptions and extensions implemented in March across Medicare quality reporting and value-based payment programs for hospitals…
Headline
The House of Representatives last night passed by unanimous consent legislation (S. 4116) extending the Paycheck Protection Program loan application period…
Perspective
As James Madison wrote in the First Amendment of our Bill of Rights, we have the right to “petition the government for a redress of grievances.” We also have…
Headline
The Federal Communications Commission’s Rural Health Care Program will carry forward up to $197.98 million in unused funds from prior years to increase…
Headline
Oklahoma voters yesterday approved expanding the state’s Medicaid initiative, the first state to do so during the COVID-19 pandemic. The ballot question, which…